 CRANBURY, N.J.--BUSINESS WIRE--Rocket Pharmaceuticals, Inc. NASDAQ: RCKT, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that previously disclosed data from the ongoing Phase 1 trial of RP-A501 in Danon Disease will be presented in a late-breaking oral presentation at the upcoming Heart Failure Society of America HFSA Annual Scientific Meeting 2021. The meeting will take place September 10-13, 20 